Alkem Laboratories has launched DSS, an original De Simone formulation probiotic, in India. This launch aims to restore gut microbiota balance and manage various gut-related health conditions. The DSS probiotic contains eight live, freeze-dried bacterial strains and is available in four strengths. The prescription probiotic market in India is valued at around INR 2,071 crore and has recorded a five-year CAGR of approximately 14%.
Probiotic DSS Launch
Alkem Laboratories Ltd. announced the launch of DSS, the original De Simone formulation probiotic blend, in India, on November 20, 2025. This probiotic aims to restore gut microbiota balance and manage various gut-related health conditions. The formulation is backed by over 80 clinical trials and 200 publications over the last two decades.
Key Features of DSS
Developed by Prof. Claudio De Simone, this proprietary probiotic combines eight carefully selected bacterial strains in precise proportions. Alkem’s DSS range will be available in four strengths: 225 billion CFU sachet, 112.5 billion CFU capsule, 45 billion CFU capsule, and 10 billion CFU capsule. Alkem is the first company offering all four strengths of this probiotic in India and also the first to launch 225 billion CFU and 10 billion CFU strengths in India.
Clinical Benefits and Indications
The DSS probiotic contains eight live, freeze-dried bacterial strains, including four Lactobacillus, three Bifidobacterium, and one Streptococcus. It is indicated for managing conditions such as Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC), Hepatic Encephalopathy (HE), and Non-Alcoholic Fatty Liver Disease (NAFLD), among others.
Market Growth and Opportunity
According to IQVIA data (MAT October 2025), the prescription probiotic market in India is valued at around INR 2,071 crore and has recorded a five-year CAGR of approximately 14%. The launch of DSS is expected to strengthen Alkem’s product portfolio in the gastrointestinal segment.
Source: BSE